Seattle's Accelerator Adds PPD as Investor | GenomeWeb
NEW YORK (GenomeWeb News) – Seattle-based biotechnology investment and management company Accelerator Corporation said today that drug discovery contract research organization PPD has joined as the sixth investor in its Accelerator III investment vehicle.
 
Accelerator provides resources to biotech companies, including capital financing, facilities, scientific and technical expertise and support, as well as business management and support.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.